Stocks That Fell to 3-Year Lows in the Week of May 25

Allergan PLC (ACT), Walgreens Boots Alliance Inc. (WBA), Dominion Energy Inc. (D), and Regeneron Pharmaceuticals Inc. (REGN) have declined to their respective three-year lows.

Author's Avatar
May 27, 2018
Article's Main Image

Allergan PLC (ACT, Financial), Walgreens Boots Alliance Inc. (WBA, Financial), Dominion Energy Inc. (D, Financial), and Regeneron Pharmaceuticals Inc. (REGN, Financial) have declined to their three-year lows.

Allergan PLC (ACT, Financial) declined to $25.28

The prices of Allergan PLC (ACT, Financial) shares have declined to $25.28 on May 25, which is only 4.2% above the 3-year low of $24.23.

Allergan PLC is an Irish international pharmaceutical company that produces both branded and generic drugs. The company also performs pharmaceutical research and development. The company’s key products include Actonel, Acuvail, Aczone, Lumigan, Namenda, Ozurdex, and Rapaflo.

Allergan PLC has a market cap of $118.76 billion; its shares were traded around $25.28 with and P/S ratio of 3.20.

On May 3 Allergan PLC announced that John Davidson has been elected to its Board of Directors. Mr. Davidson was elected on May 2 at the company’s annual general meeting of shareholders. With the addition of Mr. Davidson, the company’s board now has 12 members.

Walgreens Boots Alliance Inc. (WBA, Financial) declined to $63.53

The prices of Walgreens Boots Alliance Inc. (WBA, Financial) shares have declined to $63.53 on May 25, which is only 3.1% above the 3-year low of $61.56.

Walgreens Boots Alliance Inc. is an American holding company that owns Walgreens, Boots, and other pharmaceutical manufacturing, wholesale, and distribution companies. The company is organized into three divisions: Retail Pharmacy USA, known as Walgreens, Retail Pharmacy International, known as Boots, and Pharmaceutical Wholesale.

Walgreens Boots Alliance Inc. has a market cap of $63 billion; its shares were traded around $63.53 with a P/E ratio of 15.87 and P/S ratio of 0.53. The trailing 12-month dividend yield of Walgreens Boots Alliance Inc. stocks is 2.52%. The forward dividend yield of Walgreens Boots Alliance Inc. stocks is 2.52%. Walgreens Boots Alliance Inc. had an annual average earnings growth of 5.40% over the past 10 years.

On April 11 Walgreens Boots Alliance Inc. announced that its board of directors has declared a regular quarterly dividend of $0.40 per share, an increase of 6.7% over the year ago period. The dividend will be payable June 12 to shareholders of record at the end of business on May 18.

Dominion Energy Inc. (D, Financial) declined to $64.17

The prices of Dominion Energy Inc. (D, Financial) shares have declined to $64.17 on May 25, which is only 2.9% above the 3-year low of $62.31.

Dominion Energy Inc. is an American power and energy company that supplies electricity in Virginia and North Carolina and supplies natural gas to parts of West Virginia, Ohio, Pennsylvania, and eastern North Carolina. The company also holds generation facilities in the states of Illinois, Indiana, Connecticut, and Rhode Island.

Dominion Energy Inc. has a market cap of $41.87 billion; its shares were traded around $64.17 with a P/E ratio of 14.33 and P/S ratio of 3.25. The trailing 12-month dividend yield of Dominion Energy Inc. stocks is 4.86%. The forward dividend yield of Dominion Energy Inc. stocks is 5.22%. Dominion Energy Inc. had an annual average earnings growth of 3.60% over the past 10 years.

On May 9 Dominion Energy Inc. declared a quarterly dividend of $0.835 per share. The dividend will be payable on June 20 to shareholders of record at the close of business on June 1. The dividend is the 361st consecutive dividend that the company has paid holders.

Regeneron Pharmaceuticals Inc. (REGN, Financial) declined to $293.74

The prices of Regeneron Pharmaceuticals Inc. (REGN, Financial) shares have declined to $293.74 on May 25, which is only 4.0% above the 3-year low of $281.89.

Regeneron Pharmaceuticals Inc. is an American biotechnology company. Originally, the company focused on neurotrophic factors and their regenerative capabilities but has since branched out into the research of cytokine and tyrosine kinase receptors. The company is a component of both the NASDAQ-100 and S&P 500.

Regeneron Pharmaceuticals Inc. has a market cap of $31.68 billion; its shares were traded around $293.74 with a P/E ratio of 23.85 and P/S ratio of 5.62. Regeneron Pharmaceuticals Inc. had an annual average earnings growth of 31.70% over the past 5 years.

On May 21 Regeneron Pharmaceuticals Inc. announced that the New England Journal of Medicine has published detailed results from two Phase 3 trials for the investigational use of DUPIXENT in moderate to severe asthma. The results show that the drug significantly reduced the risk of asthma attacks and improved lung function. The trials are part of the clinical trial program that evaluated the drug in uncontrolled asthma patients.

Disclosure: I do not own stock in any of the companies mentioned in the article.